The goal of this clinical trial is to learn if the medication atomoxetine can reduce freezing of gait in people with Parkinson's disease. The main questions it aims to answer is:
Does atomoxetine reduce the frequency or severity of freezing of gait? What role does noradrenaline play in freezing of gait?
Researchers will compare atomoxetine to a placebo to see if atomoxetine can improve freezing of gait in people with Parkinson's disease.
Participants will:
Visit the study site for measurements Take atomoxetine or placebo Perform walking assessments and undergo MRI Complete questionnaires about anxiety, stress, and quality of life
Aged 18 years or older;
Diagnosis of idiopathic PD according to MDS Diagnostic Criteria;
Stabilised on optimal dopaminergic PD treatment for a minimum of four weeks prior to the baseline visit (Visit 1) and for the duration of the trial;
Presence of FOG symptoms on a daily basis;
Current and/or previous (within 3 months) participation in a clinical trial;
Any contra-indications for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker);
Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments);
Severe cognitive impairment hampering the ability to comply with the study protocol;
Radboud University Medical Center
Lead sponsor
University of Waterloo
Collaborator
Macquarie University, Australia
Collaborator